Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Sarcoma 2Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 144Carcinoma, Non-Small-Cell Lung 51Carcinoma, Transitional Cell 50Melanoma 46Urinary Bladder Neoplasms 42Prostatic Neoplasms 32Kidney Neoplasms 29Neoplasm Metastasis 27Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Hepatocellular 20Triple Negative Breast Neoplasms 15Neoplasms 15Stomach Neoplasms 14Ovarian Neoplasms 14Clear-cell metastatic renal cell carcinoma 14Lung Neoplasms 13Uterine Cervical Neoplasms 12Carcinoma, Merkel Cell 11Small Cell Lung Carcinoma 9Pancreatic Neoplasms 9Head and Neck Neoplasms 8Esophageal Neoplasms 7Breast Neoplasms 7Urethral Neoplasms 6Endometrial Neoplasms 6Cholangiocarcinoma 6Urogenital Neoplasms 5Skin Neoplasms 5Recurrence 5

Interventions

cabozantinib 1Sunitinib 1Specimen Handling 1Nivolumab 1Massage 1Magnetic Resonance Spectroscopy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HIV Infections × Nivolumab × Genitourinary × Clear all
NCT04514484 2026-05-28

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled 32 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡